Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Serous borderline tumor progressing to low-grade serous carcinoma after 35 years: a case of extended latency with molecular evidence of clonal relationship.
Journal: Gynecologic oncology reports
Published: June 22, 2026
Toward precision prognosis: Predicting recurrence-free survival in high-grade serous ovarian cancer patients using multi-time point clinical and computed tomography radiomics data.
Journal: Gynecologic oncology
Published: March 03, 2026
Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial.
Journal: Nature communications
Published: November 05, 2025
Paclitaxel-induced mitotic arrest results in a convergence of apoptotic dependencies that can be safely exploited by BCL-XL degradation to overcome cancer chemoresistance.
Journal: bioRxiv : the preprint server for biology
Published: July 16, 2025
The RAS-MEK-ERK pathway in low-grade serous ovarian cancer.
Journal: Gynecologic oncology
Published: March 28, 2025
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer.
Journal: Gynecologic oncology
Published: February 22, 2025
DirectHRD enables sensitive scar-based classification of homologous recombination deficiency.
Journal: Nucleic acids research
Published: January 07, 2025
A compendium of Amplification-Related Gain Of Sensitivity genes in human cancer.
Journal: Nature communications
Published: July 03, 2024
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses.
Journal: JCO precision oncology
Published: April 18, 2024
Endometrial Cancer Risk Among Germline BRCA1/2 Pathogenic Variant Carriers: Review of Our Current Understanding and Next Steps.
Journal: JCO precision oncology
Published: December 07, 2023
A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma.
Journal: Gynecologic oncology reports
Published: January 18, 2022
Satellite repeat RNA expression in epithelial ovarian cancer associates with a tumor-immunosuppressive phenotype.
Journal: The Journal of clinical investigation
Published: October 27, 2021
Last Updated: 09/26/2026